CELC - Celcuity Inc.

QQQ $ 584.67 $ -14.20 (-2.37 %)

DIA $ 457.94 $ -3.66 (-0.79 %)

SPY $ 652.00 $ -10.10 (-1.52 %)

TLT $ 89.23 $ 0.35 (0.39 %)

GLD $ 374.88 $ -0.11 (-0.03 %)

Previous Close

$ 94

Open

$ 94.86

Bid

$ 93.91 x 8

Ask

$ 94.03 x 100

Day's Range

$ 93.02 - $ 98.06

52 Week Range

$ 7.58 - $ 98.43

Volume

750,773

Average Volume

Market Cap

4.35B

Beta (5Y Monthly)

$ 0.52

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Wolfe Research Initiates Coverage On Celcu...
11/18/2025 16:42:54

Wolfe Research analyst Kalpit Patel initiates coverage on Celcuity (NASDAQ:CELC) with a Outperform rating and announces Pric...

Celcuity Completes Submission Of New Drug ...
11/17/2025 21:07:13

celcuity-analyst-no-longer-bullish-despite-breast-cancer-therapy-application

Celcuity Analyst No Longer Bullish Despite...
11/17/2025 15:13:15

FDA accepts NDA for Celcuity's advanced breast cancer therapy. Analyst downgrades stock due to high valuation. Next catalys...

HC Wainwright & Co. Downgrades Celcuity to...
11/17/2025 12:13:10

HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Celcuity (NASDAQ:CELC) from Buy to Neutral and raises the ...

Craig-Hallum Maintains Buy on Celcuity, Ra...
11/13/2025 17:48:50

Craig-Hallum analyst Alexander Nowak maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target from $96 to $108.

Stifel Maintains Buy on Celcuity, Raises P...
11/13/2025 16:00:31

Stifel analyst Stephen Willey maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target from $68 to $115.

Celcuity Q3 Adj. EPS $(0.78) Beats $(1.01)...
11/12/2025 21:02:26

Celcuity (NASDAQ:CELC) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(1.01) by 2...

Earnings Scheduled For November 12, 2025
11/12/2025 11:11:28

Exploring Celcuity's Earnings Expectations
11/11/2025 14:03:35

HC Wainwright & Co. Maintains Buy on Celcu...
10/22/2025 11:49:48

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price targ...

12 Health Care Stocks Moving In Monday's I...
10/20/2025 18:39:30

ww-international-replimune-group-datavault-ai-grail-and-other-big-stocks-moving-higher-on-monday

WW International, Replimune Group, Datavau...
10/20/2025 14:13:22

dow-jumps-over-200-points-cleveland-cliffs-shares-jump-after-q3-results

Dow Jumps Over 200 Points; Cleveland-Cliff...
10/20/2025 13:49:54

12 Health Care Stocks Moving In Monday's P...
10/20/2025 12:08:17

Needham Reiterates Buy on Celcuity, Mainta...
10/20/2025 10:10:53

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $70 price target.

why-delcath-systems-shares-are-trading-higher-by-over-14-here-are-20-stocks-moving-premarket

Why Delcath Systems Shares Are Trading Hig...
10/20/2025 09:10:06

Reported Saturday, Celcuity Presented Phas...
10/20/2025 08:18:12

Median radiographic progression free survival ("rPFS") was 9.1 months and the six-month rPFS rate was 67%No patients di...

Reported Saturday, Celcuity Announces Phas...
10/20/2025 08:16:32

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of...

Needham Reiterates Buy on Celcuity, Mainta...
10/03/2025 10:38:42

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $70 price target.

Celcuity To Present Phase 3 VIKTORIA-1 Bre...
09/22/2025 13:17:34

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, to...